Cleo Diagnostics is bringing to market a simple blood test for the accurate and early diagnosis of ovarian cancer.
Cleo Diagnostics
Follow
Get notifications in MyBN when activity occurs.
Lists and Charts
Share price
Company Activity
|
NEW ROLE: Lucinda Nolan, Non-Executive Director | 17 Jul 2024 |
|
|
NEW ROLE: Richard Allman, Chief Executive Officer, Executive Director | 17 Jul 2024 |
|
|
NEW ROLE: Andrew Stephens, Chief Scientific Officer, Executive Director | 17 Jul 2024 |
Related Information
Notable People
| Name | Position | Year Started |
|---|---|---|
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director |
2022 | |
Chief Scientific Officer, Executive Director
|
2022 | |
Non-Executive Director
Non-Executive Director |
2023 |
Past People
| Name | Position | Year Started | Year Ended |
|---|---|---|---|
Lead Medical Advisor, Non-Executive Director
|
2022 | ||
Non-Executive Chairman, Non-Executive Director
|
2022 | ||
Non-Executive Director
|
2023 | ||
Chief Executive Officer, Executive Director
|
2022 |
ECM Deals
| Date | Company | Transaction Type | Total Value | |
|---|---|---|---|---|
| Cleo Diagnostics | Initial public offering | $12.00m | >> |
